


#14 / SUPPL. U.S. SHEET 1 OF 1

	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,028
	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Zyskind, et al.
	(USE SEVERAL SHEETS IF NECESSARY)			FILING DATE July 23, 2001

RECEIVED  
MAR 24 2003  
TECH CENTER 1600/2900


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
	1	Gucev, et al. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 56(7):1545-1550.
	2	Partial European Search Report from co-pending Application EP 01 12 4215 dated 01/28/03.
	3	Sofia, et al. "Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228916.

S:\DOCS\DOH\DOH-7321.DOC:dmb  
030503

EXAMINER 	DATE CONSIDERED 7.25.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	